Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs
Multiple Sclerosis Journal · 2024
DOI: 10.1177/13524585241240653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Agustin Pappolla und 25 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital U…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, Treatment Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS).
Objectives
We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing–remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials.
Methods
We conducted a retrospective study and applied the Rio Score (RS), modified Rio Score (mRS), and MAGNIMS Score 12 months after DMT initiation. At 36 months, we examined their ability to predict evidence of disease activity (EDA) components and treatment failure by logistic regression analysis.
Results
Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included. At 36 months, the RS high-risk group predicted evidence of clinical activity (odds ratio (OR) 10 [2.7–36.9]) and treatment failure (OR 10.6 [3.4–32.5]) but did not predict radiological activity (OR 1.9 [0.7–5]). The mRS non-responders group did not predict EDA and treatment failure. RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder.
Conclusion
Scoring systems present different predictive abilities for disease activity parameters at 36 months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Section of Neuroradiology, Department of Radiology, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Statistics and Bioinformatics Unit, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Barcelona, Spain.
ORCID-Profile: Carmen Tur, Álvaro Cobo-Calvo, Breogán Rodríguez-Acevedo, Ana Zabalza, Rene Carvajal, Angela Vidal-Jordana, Georgina Arrambide, Jaume Sastre-Garriga, Mar Tintoré, Alex Rovira, Jordi Río
Zitieren
APA
Pappolla, A., Auger, C., Sao-Aviles, A., Tur, C., Rodriguez-Barranco, M., Cobo-Calvo, Á., Mongay-Ochoa, N., Rodríguez-Acevedo, B., Zabalza, A., Midaglia, L., Carbonell-Mirabent, P., Carvajal, R., Castilló-Justribó, J., Braga, N., Bollo, L., Vidal-Jordana, A., Arrambide, G., Nos, C., Salerno, A., …, & Río, J. (2024). Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241240653
Vancouver
Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, et al. Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241240653
BibTeX
@article{Pappolla2024,
author = {Pappolla, Agustin and Auger, Cristina and Sao-Aviles, Augusto and Tur, Carmen and Rodriguez-Barranco, Marta and Cobo-Calvo, Álvaro and Mongay-Ochoa, Neus and Rodríguez-Acevedo, Breogán and Zabalza, Ana and Midaglia, Luciana and Carbonell-Mirabent, Pere and Carvajal, Rene and Castilló-Justribó, Joaquín and Braga, Nathane and Bollo, Luca and Vidal-Jordana, Angela and Arrambide, Georgina and Nos, Carlos and Salerno, Annalaura and Galán, Ingrid and Comabella, Manuel and Sastre-Garriga, Jaume and Tintoré, Mar and Rovira, Alex and Montalban, Xavier and Río, Jordi},
title = {Prediction of disease activity and treatment failure in relapsing–remitting MS patients initiating daily oral DMTs},
journal = {Multiple Sclerosis Journal},
year = {2024},
doi = {10.1177/13524585241240653}
}
EUVIMED